Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JPMA Members Should Not Depend on Long-Listed Drugs: President Aoki
June 25, 2007
- JGPMA Proposes “Drug Benefit Standard Price” System
June 25, 2007
- Pfizer Most Active in GP Market: MOSS Survey
June 25, 2007
- GENERIC NEWS IN BRIEF
June 25, 2007
- BUSINESS NEWS IN BRIEF
June 25, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 25, 2007
- NEW PRODUCTS
June 25, 2007
- Hemorrhoid Recurrence Rate 16% 1 Year after Zione Treatment
June 25, 2007
- 14 New Kit/Report Products Included in NHI Price List
June 25, 2007
- Teijin Pharma Aims at Entering Home Health Care Business in US, Europe: Mr Ohyagi
June 25, 2007
- JPMA Explains Its Drug Pricing
June 25, 2007
- US Gov't Confirms Opposition to Yearly Revisions of NHI Prices: Policy Initiatives
June 25, 2007
- Price Gaps between Original Drugs and Generics too Large: Mr Mukai of MOF
June 25, 2007
- REGULATORY NEWS IN BRIEF
June 25, 2007
- OPINION：Be the First to Know
June 25, 2007
- Smoking Rate Drops Below 40% in Men for First Time
June 25, 2007
- 43rd ASCO Annual Meeting in Chicago(1)
June 25, 2007
- Eisai Licenses Kissei's Glufast in ASEAN Countries
June 25, 2007
- 43rd ASCO Annual Meeting in Chicago(2)
June 25, 2007
- Yakult Aims for \33 Bil. Sales by Boosting Sales of Oxaliplatin
June 25, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…